Multibagger Selection: Grok 4.7's picks
Grok 4.7 picked NTLA, VKTX, ONDS, LUNR, MGTX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.7 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | NTLA | — | 72% | — | — |
| 2 | VKTX | — | 68% | — | — |
| 3 | ONDS | — | 65% | — | — |
| 4 | LUNR | — | 62% | — | — |
| 5 | MGTX | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +7.20% | +7.82% | 1.28x | 0 |
The model's market view
Small- and mid-cap equities remain pressured by elevated rates and selective risk-off, but pockets of extreme upside exist where binary or high-conviction catalysts (regulatory decisions, commercial ramps, or contract awards) coincide with operating inflection and reasonable balance-sheet runway. Biotech and thematic growth names in the $200M–$5B range offer the highest asymmetry if execution materializes, though dilution and failure risk remain elevated.
Why each pick
NTLA
Intellia is advancing CRISPR gene-editing programs with late-stage assets. Positive Phase 3 data for lonvo-z in HAE and initiation of rolling BLA (targeting potential 1H 2027 launch) provide a verifiable path to commercial revenue. Current valuation leaves room if approval and launch materialize.
VKTX
Viking is developing oral and injectable obesity/metabolic candidates with ongoing clinical data. Positive prior Phase 2 results support further advancement; additional data and potential partnership or Phase 3 initiation are time-bound catalysts within 12 months.
ONDS
Ondas is positioned in autonomous drones and wireless infrastructure with defense and industrial applications. Projected multi-year revenue acceleration from deployments provides a growth catalyst; recent order and partnership activity supports visibility.
LUNR
Intuitive Machines is executing lunar lander and infrastructure missions under NASA and commercial contracts. Upcoming mission milestones and additional contract awards constitute verifiable catalysts.
MGTX
MeiraGTx is a gene therapy company with clinical programs advancing toward potential data or partnership milestones. Market cap under $1B leaves asymmetric upside if key programs progress.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | BKSY, LPTH, INOD, LMND, OUST |
| Gemini 3 Pro | RKLB, SOUN, LUNR, RXRX, ACHR |
| Muse Spark 1.1 | BHVN, EOSE, CAPR, SERV, MSM |
| GPT-6 | INOD, ACMR, ADMA, AMSC, TMDX |
| DeepSeek | UMAC, INOD, KRMN, SEZL, BCRX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.